Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 182

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 182
---
 •other costs incurred in seeking regulatory approval of our product candidates; and
 •payments under our license agreements. 
 

The successful development of our ProTides is highly uncertain. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. However, we do not believe that it is possible at this time to accurately project total program specific expenses through commercialization. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates to offset these expenses. Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion.
The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors including:
•the scope, rate of progress, results and expenses of our ongoing and future clinical trials, preclinical studies and research and development activities; 
 •the potential need for additional clinical trials or preclinical studies requested by regulatory agencies; 
 •potential uncertainties in clinical trial enrollment rates or drop-out or discontinuation rates of patients; 
 •competition with other drug development companies in, and the related expense of, identifying and enrolling patients in our clinical trials and contracting with third-party manufacturers for the production of the drug product needed for our clinical trials; 
 •the achievement of milestones requiring payments under in-licensing agreements; 
 •any significant changes in government regulation; 
 •the terms and timing of any regulatory approvals; 
 •the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and 
 •the ability to market, commercialize and achieve market acceptance for any of our product candidates, if approved. 
 We track research and development expenses on a program-by-program basis for both clinical-stage and preclinical product candidates. Where appropriate, manufacturing and non-clinical research and development expenses are assigned or allocated to individual product candidates.
Administrative Expenses. Administrative expenses consist of personnel costs, depreciation, amortization and other expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, bonuses, benefits and share-based payment expense. Other administrative expenses include office-related costs, professional fees and costs of our information systems. We also incur expenses as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance expenses, and expenses related to investor relations and other administrative and professional services.
Net Foreign